 LOS ANGELES--BUSINESS WIRE--- ZYNE classaction--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Zynerba Pharmaceuticals Zynerba or the Company NASDAQ: ZYNE concerning whether the board breached its fiduciary duties to shareholders. If you are a shareholder, click here to participate. On September 18, 2019, Zynerba announced results from its BELIEVE 1 Trial evaluating topical gel Zygel in children and adolescents with Developmental and Epileptic Encepha 